Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase NA 1Phase 3 1Phase 2 1

Status

Completed 5Unknown 1

Sponsor Class

OTHER 7INDUSTRY 6NIH 2OTHER_GOV 1

Study Type

Interventional 6

Sponsor

Cancer Type

Gynecologic 2Breast 2Thoracic 1Gastrointestinal 1

Conditions

Breast Neoplasms 2Pancreatic Neoplasms 1Ovarian Neoplasms 1Gynecologic Cancer 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × genexol-PM × Clear all
NCT01023347 2017-05-09

A Trial of Paclitaxel (Genexol®) and Cisplatin Versus Paclitaxel Loaded Polymeric Micelle (Genexol-PM®) and Cisplatin in Advanced Non Small Cell Lung Cancer

Samyang Biopharmaceuticals Corporation

Phase 2 Completed
276 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00882973 2017-05-05

Trial to Determine the Maximum Tolerated Dose of Genexol-PM Plus Gemcitabine and Evaluate Efficacy and Safety of Genexol-PM Regimens in Subjects With Advanced Pancreatic Cancer

Samyang Biopharmaceuticals Corporation

Phase 1 Completed
18 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT00876486 2017-05-01

Evaluate the Efficacy and Safety of Genexol®-PM Compared to Genexol® in Recurrent or Metastatic Breast Cancer

Samyang Biopharmaceuticals Corporation

Phase 3 Completed
213 enrolled
Breast

Breast Neoplasms

NCT02739529 2017-05-01

Study to Evaluate the Efficacy and Safety of Genexol-PM Once a Week for Gynecologic Cancer

Samyang Biopharmaceuticals Corporation

Phase 1 Unknown
18 enrolled
Gynecologic

Gynecologic Cancer

NCT02064829 2016-03-25

TRIBECA

Sorrento Therapeutics, Inc.

Phase NA Completed
111 enrolled
Breast

Breast Neoplasms

NCT00877253 2012-06-12

Determine MTD, Evaluate Efficacy and Safety of Genexol®-PM Plus Carboplatin With Advanced Ovarian Cancer

Samyang Biopharmaceuticals Corporation

Phase 1 Completed
18 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡